

Gilles Wandeler

List of Publications by Year in descending order

Source: <https://exaly.com/author-pdf/4923070/publications.pdf>

Version: 2024-02-01

109
papers

4,550
citations

218592

26
h-index

110317

64
g-index

111
all docs

111
docs citations

111
times ranked

5889
citing authors

#	ARTICLE	IF	CITATIONS
1	Sexual Activity Without Condoms and Risk of HIV Transmission in Serodifferent Couples When the HIV-Positive Partner Is Using Suppressive Antiretroviral Therapy. <i>JAMA - Journal of the American Medical Association</i> , 2016, 316, 171.	3.8	1,076
2	Risk of HIV transmission through condomless sex in serodifferent gay couples with the HIV-positive partner taking suppressive antiretroviral therapy (PARTNER): final results of a multicentre, prospective, observational study. <i>Lancet, The</i> , 2019, 393, 2428-2438.	6.3	627
3	Retention in care under universal antiretroviral therapy for HIV-infected pregnant and breastfeeding women (â€”Option B+â€”™) in Malawi. <i>Aids</i> , 2014, 28, 589-598.	1.0	317
4	Trends in life expectancy of HIV-positive adults on antiretroviral therapy across the globe. <i>Current Opinion in HIV and AIDS</i> , 2016, 11, 492-500.	1.5	274
5	Hepatitis C Virus Infections in the Swiss HIV Cohort Study: A Rapidly Evolving Epidemic. <i>Clinical Infectious Diseases</i> , 2012, 55, 1408-1416.	2.9	225
6	Risk Factors for Anal Cancer in Persons Infected With HIV: A Nested Case-Control Study in the Swiss HIV Cohort Study. <i>American Journal of Epidemiology</i> , 2013, 178, 877-884.	1.6	116
7	Hepatitis delta-associated mortality in HIV/HBV-coinfected patients. <i>Journal of Hepatology</i> , 2017, 66, 297-303.	1.8	101
8	Monitoring and switching of first-line antiretroviral therapy in adult treatment cohorts in sub-Saharan Africa: collaborative analysis. <i>Lancet HIV,the</i> , 2015, 2, e271-e278.	2.1	98
9	Hepatitis C virus transmission among human immunodeficiency virusâ€”infected men who have sex with men: Modeling the effect of behavioral and treatment interventions. <i>Hepatology</i> , 2016, 64, 1856-1869.	3.6	82
10	Cohort Profile Update: The Swiss HIV Cohort Study (SHCS). <i>International Journal of Epidemiology</i> , 2022, 51, 33-34j.	0.9	69
11	Outcomes of Antiretroviral Treatment Programs in Rural Southern Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 59, e9-e16.	0.9	68
12	Hepatitis B Virus Infection Is Associated With Impaired Immunological Recovery During Antiretroviral Therapy in the Swiss HIV Cohort Study. <i>Journal of Infectious Diseases</i> , 2013, 208, 1454-1458.	1.9	67
13	Weight and Metabolic Changes After Switching From Tenofovir Disoproxil Fumarate to Tenofovir Alafenamide in People Living With HIV. <i>Annals of Internal Medicine</i> , 2021, 174, 758-767.	2.0	66
14	Effectiveness of Protease Inhibitor/Nucleos(t)ide Reverse Transcriptase Inhibitorâ€”Based Second-line Antiretroviral Therapy for the Treatment of Human Immunodeficiency Virus Type 1 Infection in Sub-Saharan Africa: A Systematic Review and Meta-analysis. <i>Clinical Infectious Diseases</i> , 2018, 66, 1846-1857.	2.9	53
15	Reasons for late presentation to HIV care in Switzerland. <i>Journal of the International AIDS Society</i> , 2015, 18, 20317.	1.2	52
16	Retention in care of HIVâ€”infected pregnant and lactating women starting ART under Option B+ in rural Mozambique. <i>Tropical Medicine and International Health</i> , 2016, 21, 1003-1012.	1.0	43
17	Impact of Antiretroviral Therapy on Liver Fibrosis Among Human Immunodeficiency Virus-Infected Adults With and Without HBV Coinfection in Zambia. <i>Clinical Infectious Diseases</i> , 2017, 64, 1343-1349.	2.9	43
18	The Presence of Human Immunodeficiency Virus-Associated Neurocognitive Disorders Is Associated With a Lower Adherence to Combined Antiretroviral Treatment. <i>Open Forum Infectious Diseases</i> , 2017, 4, ofx070.	0.4	34

#	ARTICLE	IF	CITATIONS
19	HIV infection, viral hepatitis and liver fibrosis among prison inmates in West Africa. <i>BMC Infectious Diseases</i> , 2016, 16, 249.	1.3	33
20	Alcohol use, viral hepatitis and liver fibrosis among HIV-positive persons in West Africa: a cross-sectional study. <i>Journal of the International AIDS Society</i> , 2017, 20, 21424.	1.2	33
21	Research priorities to inform "Treat All" policy implementation for people living with HIV in sub-Saharan Africa: a consensus statement from the International epidemiology Databases to Evaluate AIDS (IeDEA). <i>Journal of the International AIDS Society</i> , 2019, 22, e25218.	1.2	32
22	Hepatitis C: a changing epidemic. <i>Swiss Medical Weekly</i> , 2015, 145, w14093.	0.8	32
23	Trends in hepatitis B virus testing practices and management in HIV clinics across sub-Saharan Africa. <i>BMC Infectious Diseases</i> , 2017, 17, 706.	1.3	31
24	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1359.	0.8	31
25	Incidence of hepatocellular carcinoma in HIV/HBV-coinfected patients on tenofovir therapy: Relevance for screening strategies. <i>Journal of Hepatology</i> , 2019, 71, 274-280.	1.8	31
26	Late presentation to HIV care despite good access to health services: current epidemiological trends and how to do better. <i>Swiss Medical Weekly</i> , 2016, 146, w14348.	0.8	31
27	High Rates of Hepatitis B Virus (HBV) Functional Cure Among Human Immunodeficiency Virus-HBV Coinfected Patients on Antiretroviral Therapy in Zambia. <i>Journal of Infectious Diseases</i> , 2020, 221, 218-222.	1.9	29
28	Impact of the M184V/I Mutation on the Efficacy of Abacavir/Lamivudine/Dolutegravir Therapy in HIV Treatment-Experienced Patients. <i>Open Forum Infectious Diseases</i> , 2019, 6, ofz330.	0.4	28
29	Modelling the impact of deferring HCV treatment on liver-related complications in HIV coinfecting men who have sex with men. <i>Journal of Hepatology</i> , 2016, 65, 26-32.	1.8	26
30	High prevalence of binge drinking among people living with HIV in four African countries. <i>Journal of the International AIDS Society</i> , 2018, 21, e25202.	1.2	26
31	Hepatitis B viral load in dried blood spots: A validation study in Zambia. <i>Journal of Clinical Virology</i> , 2015, 72, 20-24.	1.6	25
32	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. <i>Journal of Virus Eradication</i> , 2018, 4, 55-58.	0.3	25
33	Hepatitis B Infection, Viral Load and Resistance in HIV-Infected Patients in Mozambique and Zambia. <i>PLoS ONE</i> , 2016, 11, e0152043.	1.1	25
34	Virologic failure and HIV drug resistance on simplified, dolutegravir-based maintenance therapy: Systematic review and meta-analysis. <i>F1000Research</i> , 2018, 7, 1359.	0.8	24
35	Uptake and Discontinuation of Integrase Inhibitors (INSTIs) in a Large Cohort Setting. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 83, 240-250.	0.9	24
36	Hepatitis B treatment eligibility in West Africa: Uncertainties and need for prospective cohort studies. <i>Liver International</i> , 2017, 37, 1116-1121.	1.9	23

#	ARTICLE	IF	CITATIONS
37	Impact of Tenofovir on Hepatitis Delta Virus Replication in the Swiss Human Immunodeficiency Virus Cohort Study. <i>Clinical Infectious Diseases</i> , 2017, 64, 1275-1278.	2.9	23
38	Efficacy and safety of dolutegravir plus emtricitabine versus standard ART for the maintenance of HIV-1 suppression: 48-week results of the factorial, randomized, non-inferiority SIMPLA™HIV trial. <i>PLoS Medicine</i> , 2020, 17, e1003421.	3.9	23
39	Changes in Renal Function After Switching From TDF to TAF in HIV-Infected Individuals: A Prospective Cohort Study. <i>Journal of Infectious Diseases</i> , 2020, 222, 637-645.	1.9	22
40	Trends in HCV treatment uptake, efficacy and impact on liver fibrosis in the Swiss HIV Cohort Study. <i>Liver International</i> , 2018, 38, 424-431.	1.9	22
41	A Comparison of Initial Antiretroviral Therapy in the Swiss HIV Cohort Study and the Recommendations of the International AIDS Society-USA. <i>PLoS ONE</i> , 2011, 6, e27903.	1.1	21
42	Incident Hepatitis C Virus Infections in the Swiss HIV Cohort Study: Changes in Treatment Uptake and Outcomes Between 1991 and 2013. <i>Open Forum Infectious Diseases</i> , 2015, 2, ofv026.	0.4	20
43	Hepatitis C in HIV-infected individuals: a systematic review and meta-analysis of estimated prevalence in Africa. <i>Journal of the International AIDS Society</i> , 2016, 19, 20711.	1.2	19
44	HBV genotypes and response to tenofovir disoproxil fumarate in HIV/HBV-coinfected persons. <i>BMC Gastroenterology</i> , 2015, 15, 79.	0.8	18
45	Prevalence and Outcomes of Hepatitis B Coinfection and Associated Liver Disease Among Antiretroviral Therapy-Naïve Individuals in a Rural Tanzanian Human Immunodeficiency Virus Cohort. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw162.	0.4	18
46	Liver fibrosis in treatment-naïve HIV-infected and HIV/HBV co-infected patients: Zambia and Switzerland compared. <i>International Journal of Infectious Diseases</i> , 2016, 51, 97-102.	1.5	18
47	Molecular epidemiology of hepatitis B virus infection in Switzerland: a retrospective cohort study. <i>BMC Infectious Diseases</i> , 2015, 15, 483.	1.3	17
48	Absence of hepatitis delta infection in a large rural HIV cohort in Tanzania. <i>International Journal of Infectious Diseases</i> , 2016, 46, 8-10.	1.5	17
49	Prevalence of hepatitis B and delta according to HIV-type: a multi-country cross-sectional survey in West Africa. <i>BMC Infectious Diseases</i> , 2017, 17, 466.	1.3	17
50	Impact of Direct-Acting Antivirals on the Burden of HCV Infection Among Persons Who Inject Drugs and Men Who Have Sex With Men in the Swiss HIV Cohort Study. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy154.	0.4	17
51	Prevention and Care of Hepatitis B in Senegal; Awareness and Attitudes of Medical Practitioners. <i>American Journal of Tropical Medicine and Hygiene</i> , 2017, 97, 389-395.	0.6	16
52	Clinical Outcomes of 2-Drug Regimens vs 3-Drug Regimens in Antiretroviral Treatment—Experienced People Living With Human Immunodeficiency Virus. <i>Clinical Infectious Diseases</i> , 2021, 73, e2323-e2333.	2.9	16
53	Elevated AST-to-platelet ratio index is associated with increased all-cause mortality among HIV-infected adults in Zambia. <i>Liver International</i> , 2015, 35, 1886-1892.	1.9	15
54	Association between hepatitis B coinfection and elevated liver stiffness among HIV-infected adults in Lusaka, Zambia. <i>Tropical Medicine and International Health</i> , 2016, 21, 1435-1441.	1.0	15

#	ARTICLE	IF	CITATIONS
55	Field performance of the Determine HBsAg point-of-care test for diagnosis of hepatitis B virus co-infection among HIV patients in Zambia. <i>Journal of Clinical Virology</i> , 2018, 98, 5-7.	1.6	15
56	The current situation and challenges of screening for and treating hepatitis B in sub-Saharan Africa. <i>Expert Review of Gastroenterology and Hepatology</i> , 2018, 12, 537-546.	1.4	15
57	Prevalence of liver cirrhosis in individuals with hepatitis B virus infection in sub-Saharan Africa: Systematic review and meta-analysis. <i>Liver International</i> , 2021, 41, 710-719.	1.9	15
58	The J-Curve in HIV. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2016, 71, 302-309.	0.9	14
59	Zidovudine impairs immunological recovery on first-line antiretroviral therapy. <i>Aids</i> , 2013, 27, 2225-2232.	1.0	13
60	Brief Report: Switching From TDF to TAF in HIV/HBV-Coinfected Individuals With Renal Dysfunction—A Prospective Cohort Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2020, 85, 227-232.	0.9	13
61	Tenofovir in Second-Line ART in Zambia and South Africa. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2012, 61, 41-48.	0.9	12
62	Chronic Hepatitis B Virus Coinfection Is Associated With Renal Impairment Among Zambian HIV-Infected Adults. <i>Clinical Infectious Diseases</i> , 2014, 59, 1757-1760.	2.9	12
63	HIV drug resistance in sub-Saharan Africa: public health questions and the potential role of real-world data and mathematical modelling. <i>Journal of Virus Eradication</i> , 2018, 4, 55-58.	0.3	12
64	Bridging the gap between HIV epidemiology and antiretroviral resistance evolution: Modelling the spread of resistance in South Africa. <i>PLoS Computational Biology</i> , 2019, 15, e1007083.	1.5	11
65	The Impact of Binge Drinking on Mortality and Liver Disease in the Swiss HIV Cohort Study. <i>Journal of Clinical Medicine</i> , 2021, 10, 295.	1.0	11
66	Performance of HBsAg point-of-care tests for detection of diagnostic escape-variants in clinical samples. <i>Journal of Clinical Virology</i> , 2015, 69, 33-35.	1.6	10
67	Absence of Active Hepatitis C Virus Infection in Human Immunodeficiency Virus Clinics in Zambia and Mozambique. <i>Open Forum Infectious Diseases</i> , 2016, 3, ofw049.	0.4	10
68	Awareness and management of elevated blood pressure among human immunodeficiency virus-infected adults receiving antiretroviral therapy in urban Zambia: a call to action. <i>Global Health Action</i> , 2017, 10, 1359923.	0.7	10
69	Clinical outcomes in persons coinfecting with HIV and HCV: Impact of HCV treatment. <i>Clinical Infectious Diseases</i> , 2020, 70, 2131-2140.	2.9	9
70	Clusters of Sexual Behavior in Human Immunodeficiency Virus-positive Men Who Have Sex With Men Reveal Highly Dissimilar Time Trends. <i>Clinical Infectious Diseases</i> , 2019, 70, 416-424.	2.9	9
71	Elimination of Viral Hepatitis in Low and Middle-Income Countries: Epidemiological Research Gaps. <i>Current Epidemiology Reports</i> , 2021, 8, 89-96.	1.1	9
72	Medication Side Effects and Retention in HIV Treatment: A Regression Discontinuity Study of Tenofovir Implementation in South Africa and Zambia. <i>American Journal of Epidemiology</i> , 2018, 187, 1990-2001.	1.6	8

#	ARTICLE	IF	CITATIONS
73	The hepatitis C cascade of care in HIV/hepatitis C virus coinfecting individuals in Europe: regional and intra-regional differences. <i>Aids</i> , 2022, 36, 423-435.	1.0	8
74	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. <i>PLoS Medicine</i> , 2020, 17, e1003397.	3.9	7
75	Rates and predictors of switching to tenofovir alafenamide-containing ART in a nationwide cohort. <i>BMC Infectious Diseases</i> , 2019, 19, 834.	1.3	6
76	Switch to etravirine for HIV-positive patients receiving statin treatment: a prospective study. <i>European Journal of Clinical Investigation</i> , 2015, 45, 720-730.	1.7	5
77	Tenofovir Alafenamide in Multimorbid HIV-Infected Patients With Prior Tenofovir-Associated Renal Toxicity. <i>Open Forum Infectious Diseases</i> , 2018, 5, ofy275.	0.4	5
78	Hepatosplenic schistosomiasis in Zambian adults is characterized by increased liver stiffness: A nested case-control study. <i>Heliyon</i> , 2020, 6, e04534.	1.4	5
79	Hepatitis C among men who have sex with men: knowing your epidemic. <i>The Lancet Gastroenterology and Hepatology</i> , 2021, 6, 5-6.	3.7	5
80	Acquired HIV drug resistance mutations on first-line antiretroviral therapy in Southern Africa: Systematic review and Bayesian evidence synthesis. <i>Journal of Clinical Epidemiology</i> , 2022, 148, 135-145.	2.4	5
81	Tenofovir or zidovudine in second-line antiretroviral therapy after stavudine failure in southern Africa. <i>Antiviral Therapy</i> , 2013, 19, 521-525.	0.6	4
82	Fewer pills do not mean fewer drug-drug interactions. <i>Aids</i> , 2018, 32, 676-678.	1.0	4
83	A closer look at the spectrum of drug-induced liver injury in sub-Saharan Africa. <i>Expert Review of Clinical Pharmacology</i> , 2019, 12, 875-883.	1.3	4
84	Chronic hepatitis B virus mono-infection at a university hospital in Zambia. <i>World Journal of Hepatology</i> , 2018, 10, 622-628.	0.8	4
85	HCV reinfection after HCV therapy among HIV/HCV-coinfecting individuals in Europe. <i>HIV Medicine</i> , 2022, 23, 684-692.	1.0	4
86	No Impact of Hepatitis B Virus Infection on Early Mortality Among Human Immunodeficiency Virus-Infected Patients in Southern Africa. <i>Clinical Infectious Diseases</i> , 2018, 67, 1310-1311.	2.9	3
87	Effectiveness and Safety of Interferon-Free Direct-Acting Antiviral Hepatitis C Virus Therapy in HIV/Hepatitis C Virus Coinfecting Individuals: Results From a Pan-European Study. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2021, 86, 248-257.	0.9	3
88	Hepatitis B screening practices and viral control among persons living with HIV in urban Senegal. <i>Journal of Viral Hepatitis</i> , 2021, . .	1.0	3
89	Issues with measuring hepatitis prevalence in resource-limited settings. <i>Lancet</i> , 2018, 391, 835-836.	6.3	2
90	Brief Report: Assessing the Association Between Changing NRTIs When Initiating Second-Line ART and Treatment Outcomes. <i>Journal of Acquired Immune Deficiency Syndromes (1999)</i> , 2018, 77, 413-416.	0.9	2

#	ARTICLE	IF	CITATIONS
91	Modelling the impact of different testing strategies for HCV infection in Switzerland. <i>Journal of Virus Eradication</i> , 2019, 5, 191-203.	0.3	2
92	The association between hepatitis B virus infection and nonliver malignancies in persons living with HIV: results from the EuroSIDA study. <i>HIV Medicine</i> , 2022, 23, 585-598.	1.0	2
93	An Approach to Quantifying the Interaction between Behavioral and Transmission Clusters. <i>Viruses</i> , 2022, 14, 784.	1.5	2
94	Non-AIDS defining malignancies in the combination ART era: immunological and socio-behavioral risk factors. <i>F1000Research</i> , 0, 8, 1400.	0.8	1
95	Influence of Hepatitis C Coinfection and Treatment on Risk of Diabetes Mellitus in HIV-Positive Persons. <i>Open Forum Infectious Diseases</i> , 2020, 7, ofaa470.	0.4	1
96	Response to "Is AST-to-platelet ratio a reliable tool in HIV patients in Africa?". <i>Liver International</i> , 2015, 35, 2060-2060.	1.9	0
97	Hepatitis B Therapy as HIV Prevention in Africa: A Case Series From Zambia. <i>Hepatology</i> , 2019, 69, 458-460.	3.6	0
98	Hepatitis D virus: is it all in the family?. <i>Gut</i> , 2020, 69, 1162-1163.	6.1	0
99	Pharmacokinetic parameters and weight change in HIV patients newly switched to dolutegravir-based regimens in SIMPL'HIV clinical trial. <i>British Journal of Clinical Pharmacology</i> , 2021, 87, 4455-4460.	1.1	0
100	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
101	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
102	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
103	Impact of scaling up dolutegravir on antiretroviral resistance in South Africa: A modeling study. , 2020, 17, e1003397.		0
104	Title is missing!. , 2020, 17, e1003421.		0
105	Title is missing!. , 2020, 17, e1003421.		0
106	Title is missing!. , 2020, 17, e1003421.		0
107	Title is missing!. , 2020, 17, e1003421.		0
108	Title is missing!. , 2020, 17, e1003421.		0

#	ARTICLE	IF	CITATIONS
109	Title is missing!. , 2020, 17, e1003421.		0